After Hours
There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. Recently, Yahoo Finance discussed the stock, revealing that Bristol Myers Squibb Expands Health Equity Grant Initiatives to Improve Health Outcomes.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Stocks Info
This NYSE-listed company operates within the Drug Manufacturers – General industry segment, falling under the Healthcare sector. The current market capitalization of Bristol-Myers Squibb Co. is $106.27B. A total of 9.76 million shares were traded on the day, compared to an average of 16.76M shares.
In the most recent transaction, BOERNER CHRISTOPHER S. bought 2,000 shares of BMY for 49.78 per share on Dec 05 ’23. After the transaction, the Chief Executive Officer now owns 82,672 company shares. In a previous transaction on Nov 28 ’23, BOERNER CHRISTOPHER S. bought 3,071 shares at 48.86 per share. BMY shares that Chief Executive Officer owns now total 79,384.
Among the insiders who bought shares, Samuels Theodore R. II acquired of 8,500 shares on Nov 20 ’23 at a per-share price of $49.81. This resulted in the Director holding 35,500 shares of BMY after the transaction. In another insider transaction, Powell Ann sold 17,986 shares at $61.25 per share on Aug 24 ’23. Company shares held by the EVP, Chief Human Resources now total 27,868.
Dividend
The income generated by dividends is an indication that a company is improving its financial position, which is why investors prefer companies paying dividends. Bristol-Myers Squibb Co. pays an annual dividend of $2.31, resulting in a dividend yield of 4.40%, and it has a price to earnings (P/E) ratio of 13.62. BMY’s most recent ex-dividend date was 4/4/2024 when it declared a $0.60 quarterly dividend that was paid in cash on 5/1/2024. Previously, the company paid the dividend on 2/1/2024 with an ex-dividend date of 1/4/2024. The BMY stock dividend was $0.60 per share in cash.
Even though price targets are rarely accurate, they do tend to exert some kind of influence from time to time and are often considered important by markets. In terms of 52-week highs and lows, BMY has a high of $71.07 and a low of $47.58.
As of this writing, BMY has an earnings estimate of $1.47 per share for the current quarter. EPS was calculated based on a consensus of 16 estimates, with a high estimate of $1.79 per share and a lower estimate of $1.2. The company reported an EPS of $1.82 in the last quarter, which was 13.00% higher than expectations of $1.61.
Balance Sheet Annually/Quarterly
In a balance sheet, you can see what assets and liabilities the company has, as well as how much equity investors have invested. These figures can be used to calculate a company’s financial ratios to give investors a better idea of its prospects. BMY’s latest balance sheet shows that the firm has $17.22B in Cash & Short Term Investments as of fiscal 2021. There were $45.60B in debt and $21.87B in liabilities at the time. Its Book Value Per Share was $14.56, while its Total Shareholder’s Equity was $36.01B.
Analysts Opinion
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for BMY is Buy with a score of 3.27.
